• 7ACC2 in Cancer Immunometabolism: Beyond MCT1 Inhibition

  2026-05-19

  Explore how 7ACC2, a potent monocarboxylate transporter 1 inhibitor, uniquely enables interrogation of lactate dynamics and immunometabolic checkpoints in cancer. This article integrates recent advances from immunology to provide actionable insight for advanced cancer metabolism research.

• T0070907: Precision PPARγ Antagonist for Advanced Cellular R

  2026-05-18

  T0070907 is a nanomolar PPARγ antagonist enabling precise modulation of PPARγ signaling pathways in adipogenesis, cancer biology, and inflammatory models. Its selectivity and robust performance streamline experimental reproducibility and troubleshooting for both routine and specialized assays.

• Suhuang Capsule Attenuates ER Stress and NLRP3 Activation in

  2026-05-18

  This study demonstrates that Suhuang antitussive capsule ameliorates pulmonary dysfunction in a rat model of cough variant asthma (CVA) by suppressing endoplasmic reticulum (ER) stress and downstream NLRP3 inflammasome activation. The findings clarify the mechanistic links between ER stress, mitochondrial dynamics, and inflammasome-mediated inflammation in CVA, providing a pharmacological rationale for targeting these pathways in respiratory disease.

• Anisomycin as a JNK Agonist: Applied Workflows & Troubleshoo

  2026-05-17

  Anisomycin is a potent and specific JNK agonist instrumental for dissecting apoptosis and cellular stress pathways. This guide details deployment strategies, protocol optimization, and troubleshooting for maximizing its impact in cancer cell and neurobiology research, drawing on evidence from both oncology and advanced memory maintenance studies.

• COX-2 Pathway Modulation in Bothropic Venom-Induced Muscle R

  2026-05-16

  This study investigates how selective COX-2 inhibition with lumiracoxib affects tissue ischemia and revascularization after skeletal muscle injury from Bothrops asper venom. The findings reveal that early COX-2 blockade worsens acute ischemia but enhances late-stage angiogenic responses, providing new temporal insights for muscle regeneration research.

• Reserpine (SKU N1867): Technical Use in Neuropharmacology Re

  2026-05-15

  Reserpine provides a high-purity, workflow-stable tool for laboratory studies focused on neurotransmitter depletion and antihypertensive mechanism research. It is not suitable for diagnostic or therapeutic applications due to its potent bioactivity and research-use-only designation.

• Lenalidomide (CC-5013): Integrating Epigenetic Synergy in My

  2026-05-15

  Explore how Lenalidomide (CC-5013) synergizes with epigenetic modulators to enhance anti-myeloma immune responses. This article provides in-depth analysis, unique protocol guidance, and new insights for immunomodulatory research.

• Protease Inhibitor Cocktail (100X): Precision in Protein Pre

  2026-05-14

  Explore how the Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) delivers advanced protein degradation prevention and assay reliability. This article uniquely connects molecular mechanism, assay design, and translational research insights to set a new benchmark for protease inhibition strategies.

• Super-Enhancer Hijacking of LINC01977 Drives Early LUAD via

  2026-05-14

  Zhang et al. (2022) identified that super-enhancer-driven upregulation of the lncRNA LINC01977 promotes malignancy in early-stage lung adenocarcinoma, mechanistically linking tumor-associated macrophage infiltration to TGF-β/SMAD3 pathway activation. This work highlights novel epigenetic vulnerabilities and suggests new molecular targets for translational epigenetics and cancer biology research.

• Sulfamonomethoxine: Protocols and Troubleshooting in Applied

  2026-05-13

  Sulfamonomethoxine (SMM) unlocks robust, reproducible workflows for researchers targeting veterinary and aquatic infections, as well as environmental toxicity benchmarks. This guide translates APExBIO’s research-grade SMM into actionable protocols, troubleshooting strategies, and workflow enhancements that outperform generic sulfonamide approaches.

• A 83-01: Selective ALK-5 Inhibitor for TGF-β Pathway Researc

  2026-05-13

  A 83-01, a potent ALK-5 inhibitor, enables precise suppression of TGF-β signaling in diverse biological models. Its nanomolar potency and selectivity for ALK-5, ALK-4, and ALK-7 underpin applications in EMT, organoid, and stemness studies. This article details its mechanism, benchmarks, and practical integration for advanced research.

• DAT Neuroimaging Tracks Dopaminergic Neuron Maturation in PD

  2026-05-12

  Goggi et al. (2020) establish that dopamine transporter (DAT) neuroimaging provides a reliable, non-invasive method for monitoring the maturation of transplanted human embryonic stem cell-derived dopaminergic neurons in preclinical Parkinson’s models. This approach advances assessment of cell therapy efficacy and has direct implications for optimizing transplantation protocols and longitudinal outcome measurement.

• Canagliflozin’s Effects on Mitochondria in Diabetic Kidney D

  2026-05-12

  This study offers novel evidence that Canagliflozin, beyond lowering glucose, induces structural and functional improvements in proximal tubular cell mitochondria in hypertensive–diabetic mice. The findings suggest mitochondrial remodeling may underlie the kidney-protective actions of SGLT2 inhibition, with implications for mechanistic diabetes and nephropathy research.

• Alda 1: ALDH2 Activator for Cardiac Ischemia and Dermatitis

  2026-05-11

  Alda 1 is a potent small molecule ALDH2 activator that enhances both wild-type and ALDH2*2 variant enzymatic function. Evidence shows it doubles wild-type ALDH2 activity and restores mutant function elevenfold, supporting cardioprotection in ischemia and mitigation of radiation-induced dermatitis. Its robust chemical and biological properties make Alda 1 a key tool in advanced cardiac research and aldehyde detoxification studies.

• ATM Inhibition Synergizes with Fenofibrate in Ovarian Cancer

  2026-05-11

  This study uncovers a synergistic effect between ATM kinase inhibition and fenofibrate in high grade serous ovarian cancer (HGSOC) cells, particularly those with proficient homologous recombination. By linking DNA damage response signaling to metabolic vulnerabilities, the research suggests new combination therapy strategies for chemoresistant HGSOC.

15801 records 1/1054 page Next 12345 下5页 Last page